Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lantern Pharma Q2 2024 GAAP EPS $(0.46) Beats $(0.55) Estimate

Author: Benzinga Newsdesk | August 08, 2024 04:45pm
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 4.55 percent decrease over losses of $(0.44) per share from the same period last year.

Posted In: LTRN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist